Neurogene Inc. (NASDAQ:NGNE) Receives Average Recommendation of “Moderate Buy” from Analysts

Neurogene Inc. (NASDAQ:NGNE) has been given a consensus rating of “Moderate Buy” by the seven research firms that are presently covering the company, Marketbeat reports. One research analyst has rated the stock with a sell rating, one has given a hold rating and five have assigned a buy rating to the company. The average 1-year target price among brokerages that have updated their coverage on the stock in the last year is $44.00.

A number of brokerages recently issued reports on NGNE. HC Wainwright restated a “buy” rating and set a $70.00 target price on shares of Neurogene in a research report on Tuesday, January 13th. Wall Street Zen lowered Neurogene from a “hold” rating to a “sell” rating in a research note on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Neurogene in a research report on Thursday, January 22nd. Finally, Lifesci Capital initiated coverage on Neurogene in a research note on Monday, January 26th. They issued an “outperform” rating and a $50.00 target price for the company.

Neurogene Price Performance

Neurogene stock opened at $18.62 on Friday. Neurogene has a 12-month low of $6.88 and a 12-month high of $37.27. The stock has a market capitalization of $288.42 million, a P/E ratio of -4.53 and a beta of 1.59. The firm’s 50-day moving average is $18.68 and its two-hundred day moving average is $21.48.

Institutional Investors Weigh In On Neurogene

Several hedge funds have recently modified their holdings of NGNE. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Neurogene by 17.9% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares during the last quarter. Jennison Associates LLC increased its holdings in shares of Neurogene by 55.0% during the 2nd quarter. Jennison Associates LLC now owns 167,563 shares of the company’s stock worth $2,505,000 after buying an additional 59,479 shares during the last quarter. PNC Financial Services Group Inc. raised its position in shares of Neurogene by 43.6% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,055 shares of the company’s stock worth $61,000 after buying an additional 1,232 shares during the period. Schroder Investment Management Group acquired a new position in Neurogene in the second quarter valued at $451,000. Finally, Bank of America Corp DE grew its position in Neurogene by 81.6% during the second quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock valued at $1,426,000 after acquiring an additional 42,880 shares during the period. 52.37% of the stock is owned by institutional investors and hedge funds.

About Neurogene

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.